Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT02613598
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in patients with relapsed or refractory Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL).

Key Dates

Start date
May 12, 2016
Status verified
Dec 2021
Primary completion
Jun 7, 2021
Completion
Jun 7, 2021

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bortezomib and Ruxolitinib
    Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.

Primary Outcome Measure

The Maximum Tolerated Dose (MTD) of Ruxolitinib in Combination with Standard Dose Bortezomib [ Time Frame: Up to 5 Years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michgan Comprehensive Cancer CenterAnn ArborMichigan48187-

Find similar trials in Ann Arbor, MI

By research site
University of Michgan Comprehensive Cancer Center· Ann Arbor, MI

Related Studies